Literature DB >> 14680413

Factors influencing compliance in schizophrenia patients.

W Wolfgang Fleischhacker1, Maria A Oehl, Martina Hummer.   

Abstract

Scientifically, compliance can be expressed as the ratio between an observed treatment behavior and given treatment standards. Although the factors that influence compliance often overlap or influence each other, it is possible to differentiate between factors that are related to the patient, the patient's environment, the treating clinician, and treatment itself. Although this differentiation is in some ways artificial, it may aid the practicing clinician in assessing the various reasons why a particular patient is likely to develop or has already developed compliance problems. The fact that a number of circumstances and parties are involved in the multifaceted issue of compliance makes it evident that patients must never be solely blamed for compliance problems. Despite the fact that compliance behavior is difficult to study from a methodological point of view, the scientific information available to date does provide many important leads for the engaged clinician to prevent and manage compliance problems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14680413

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  29 in total

Review 1.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

2.  Modelling the treated course of schizophrenia: development of a discrete event simulation model.

Authors:  Bart Heeg; Erik Buskens; Martin Knapp; Gerda van Aalst; Pieter J T Dries; Lieuwe de Haan; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Factors influencing adherence in children and adolescents treated with antipsychotics or antidepressants.

Authors:  Kurosch Yazdi; Gabriele Unterlass; Georg Kemmler; Karl Kralovec; Wolfgang Aichhorn
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

4.  Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.

Authors:  Kenneth L Subotnik; Keith H Nuechterlein; Joseph Ventura; Michael J Gitlin; Stephen Marder; Jim Mintz; Gerhard S Hellemann; Leslie A Thornton; Indira R Singh
Journal:  Am J Psychiatry       Date:  2011-01-04       Impact factor: 18.112

5.  Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.

Authors:  Joseph Peuskens; Jitendra Trivedi; Sergiy Malyarov; Martin Brecher; Ola Svensson; Frank Miller; Inger Persson; Didier Meulien
Journal:  Psychiatry (Edgmont)       Date:  2007-11

6.  Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.

Authors:  Mamta Sapra; Ipsit V Vahia; Pia N Reyes; Paul Ramirez; Carl I Cohen
Journal:  Schizophr Res       Date:  2008-10-11       Impact factor: 4.939

7.  Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry.

Authors:  Tongeji Elifazi Tungaraza; Pravija Talapan-Manikoth; Rosemary Jenkins
Journal:  Ther Adv Drug Saf       Date:  2013-04

8.  Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.

Authors:  Y Barak; I Mirecki; H Y Knobler; Z Natan; D Aizenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-02-04       Impact factor: 4.530

9.  Self-stigma, stages of change and psychosocial treatment adherence among Chinese people with schizophrenia: a path analysis.

Authors:  Kelvin M T Fung; Hector W H Tsang; Fong Chan
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-08-02       Impact factor: 4.328

10.  Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders.

Authors:  Nick C Patel; M Lynn Crismon; Alan Shafer; Anthony De Leon; Molly Lopez; Daniel C Lane
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-02-08       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.